This piece was originally published in November 2019 on CellandGene.com We are living through one of the most exciting eras biopharmaceutical science has ever seen. Following the first U.S. and European regulatory approvals of gene therapies and CAR-T therapies in recent years, activity in this industry has skyrocketed. In the U.S., more than 800 clinical…
Coordinating the collection and delivery of cells for cell and gene therapy developers begins long before the first patient or donor is collected. Our Be The Match BioTherapies® Collection Network Liaison team works with cell and gene therapy clients to understand their needs. Then, they use established, standardized approaches to onboard, audit and train the…
For cell and gene therapy companies developing allogeneic therapies, including allogeneic CAR-T or T-cell immunotherapies, getting high-quality starting material from healthy adult donors is critical to the success of their therapies. But, what is it like to be the allogeneic donors who get the call asking them to be volunteer donors? And why would they…
What if you could shorten the time it takes to activate apheresis and cell collection sites to begin collecting starting material for your cell or gene therapy and simultaneously create efficiencies for those sites? A standardized quality system audit (QSA) program, like the Quality System Audit Program (QSAP) offered by Be The Match BioTherapies®, helps…
It’s no secret that cell and gene therapies are advancing at a rapid pace. As with any new innovations, unforeseen challenges are sure to accompany. One of the challenges generating buzz lately, is the need to define standards in the industry, specifically in the areas of apheresis collection and manufacturing. So, we’re going straight to…
Last month, Jamie Margolis, PhD, who has been with Be The Match BioTherapies® since its inception, was promoted to Director of Product Development Operations. We spoke with her about key challenges the cell therapy industry is facing and how Be The Match BioTherapies is positioned, and growing, to help companies advance their cell or gene…